The exact role of opioid receptors in drug addiction and modulatory mechanism of action of monovalent cations on these receptors are still not fully understood. Our results support the view that the mechanism of addiction to morphine is primarily based on desensitization of μ- and δ-opioid receptors. Desenzitization of agonist response proceeds already at the level of G protein functional activity. Long-term exposure of rats to morphine resulted in increase of number of δ-opioid receptors and change of their sensitivity to sodium ions. Analysis of the effect of different monovalent ions on agonist binding in δ-OR- Gi1α (Cys351 -Ile351 )-HEK293 cell line confirmed the preferential sensitivity of δ-opioid receptor to sodium ions. We have distinguished the high- and low-affinity Na+ sites. Biophysical analysis of interaction of lithium, sodium, potassium and cesium ions with plasma membranes isolated from HEK293 cells with the help of fluorescent probes indicated that monovalent ions interact, in low-affinity manner, with the polar, membrane-water interface of membrane bilayer. Key words: morphine, forebrain cortex, opioid receptors, G proteins, monovalent ions, plasma membrane, fluorescence spectroscopy.

A técnica de laserterapia é um método não-invasivo que demonstra clinicamente ser eficaz na redução da sensibilidade à dor. O presente estudo visou examinar os efeitos da aplicação do LASER sobre a sensibilidade dolorosa induzida pela constrição crônica do nervo isquiático (CCI) de ratos. Os animais foram submetidos a ensaios comportamentais e a dez sessões de laserterapia. Observamos melhora para os testes comportamentais o que corrobora com os ensaios de imunoblotting no gânglio da raiz dorsal, onde observamos uma diminuição de Substância P no grupo de animais tratados com LASER. Com relação aos ensaios imunoenzimático de ELISA, observamos diminuição de citocinas pró-inflamatória e uma tendência ao aumento de citocina anti-inflamatória. Não observamos diferença estatística na análise dos receptores opióides MOR , DOR e KOR . Podemos concluir que o LASER é eficaz e age na modulação da dor neuropática. / The technique of laser therapy is a not invasive method that demonstrates clinically to be effective in reducing sensitivity to pain. This study aimed to examine the effects of application of LASER on pain sensitivity induced by chronic constriction of the sciatic nerve (CCI) in rats. The animals were subjected to behavioral tests and the ten sessions of laser therapy. We observed and improvement for behavioral tests which corroborates with immunoblotting assays in the dorsal root ganglion, where we observes a decrease of substance P in the group of animals treated with LASER. Regarding immunoenzymatic ELISA assay, we observed a decrease of pro-inflammatory cytokines and a possible increase in anti-inflammatory cytokine. No statistical difference in the analysis of opioid receptor MOR, DOR and KOR.

A técnica de laserterapia é um método não-invasivo que demonstra clinicamente ser eficaz na redução da sensibilidade à dor. O presente estudo visou examinar os efeitos da aplicação do LASER sobre a sensibilidade dolorosa induzida pela constrição crônica do nervo isquiático (CCI) de ratos. Os animais foram submetidos a ensaios comportamentais e a dez sessões de laserterapia. Observamos melhora para os testes comportamentais o que corrobora com os ensaios de imunoblotting no gânglio da raiz dorsal, onde observamos uma diminuição de Substância P no grupo de animais tratados com LASER. Com relação aos ensaios imunoenzimático de ELISA, observamos diminuição de citocinas pró-inflamatória e uma tendência ao aumento de citocina anti-inflamatória. Não observamos diferença estatística na análise dos receptores opióides MOR , DOR e KOR . Podemos concluir que o LASER é eficaz e age na modulação da dor neuropática. / The technique of laser therapy is a not invasive method that demonstrates clinically to be effective in reducing sensitivity to pain. This study aimed to examine the effects of application of LASER on pain sensitivity induced by chronic constriction of the sciatic nerve (CCI) in rats. The animals were subjected to behavioral tests and the ten sessions of laser therapy. We observed and improvement for behavioral tests which corroborates with immunoblotting assays in the dorsal root ganglion, where we observes a decrease of substance P in the group of animals treated with LASER. Regarding immunoenzymatic ELISA assay, we observed a decrease of pro-inflammatory cytokines and a possible increase in anti-inflammatory cytokine. No statistical difference in the analysis of opioid receptor MOR, DOR and KOR.

Le by-pass gastrique Roux-en-Y (BPG) est une chirurgie de l'obésité qui induit des améliorations spectaculaires de l'homéostasie glucidique indépendamment de la perte de poids. Un mécanisme proposé pour expliquer ces améliorations est une augmentation de la production intestinale de glucose (PIG) qui induit des effets bénéfiques sur l'organisme (satiété, amélioration de la sensibilité hépatique à l'insuline). Cette augmentation de la PIG, retrouvée chez la souris ayant subi un BPG simplifié, est également responsable des effets bénéfiques des régimes enrichis en protéines via l'inhibition des récepteurs mu-opioïdes (RMO) par les peptides. Nous avons donc testé l'hypothèse selon laquelle les effets bénéfiques du BPG dépendraient d'une inhibition des RMO par les protéines alimentaires et nous avons également testé le rôle causal de la PIG dans ces améliorations métaboliques. Pour cela, nous avons réalisé un by-pass duodéno-jéjunal (BDJ), ie un BPG sans restriction gastrique, chez des souris sauvages (WT), des souris invalidées pour le gène du RMO (MOR-/-) et des souris dépourvues de PIG (I-G6pc-/-). Chez les souris obèses, Le BDJ induit une forte perte de poids (–30%), en partie expliquée par une malabsorption lipidique, ainsi qu'une amélioration des paramètres glucidiques dépendante de cette perte de poids. Au contraire, chez la souris de poids normal, le BDJ n'induit ni perte de poids ni malabsorption mais améliore la tolérance au glucose. Les effets sont les mêmes chez les souris WT, MOR-/- et I-G6pc-/- ce qui montre que les récepteurs mu-opioïdes et la PIG ne semblent pas avoir de rôle causal dans les améliorations du métabolisme énergétique et glucidique après BDJ / Roux-en-Y gastric bypass procedure (GBP) is an obesity surgery that induces dramatic glucose homeostasis improvements independently of weight loss. A proposed mechanism to explain these glucose homeostasis improvements is an increase in intestinal glucose production (IGP) that induces beneficial effects on metabolism (satiety, improved liver insulin sensitivity). This increase in IGP is found in mice that have undergone a simplified GBP and is also responsible for the beneficial effects of protein-enriched diets through the inhibition of mu-opioid receptors (MOR) by alimentary peptides. We therefore hypothesized that the beneficial effects of GBP could depend on MOR inhibition by dietary proteins and we also tested the causal role of IGP in these metabolic improvements. For this purpose, we performed a duodenal-jejunal bypass surgery (DJB), ie GBP without gastric restriction, in wild-type mice (WT), in mice lacking MOR gene (MOR-/-) and in mice lacking IGP (IG6pc-/-). In obese mice, DJB induced a rapid and substantial weight loss (-30%), partly explained by fat malabsorption, and weight loss-dependent improvements of glucose homeostasis. In contrast, in the non-obese mice, DJB did not induce weight loss nor malabsorption but improved glucose tolerance. Effects were similar in WT, MOR-/- and I-G6pc-/- mice showing that mu-opioid receptors and IGP did not appear to have a causal role in glucose and energy metabolism improvements after DJB

<p>G-protein coupled receptors (GPCRs) are membrane proteins that constitute ~30% of the FDA-approved drug targets. Opioid receptors are a subtype of GPCRs with four different receptor types: delta, kappa, mu, and nociception opioid receptors. Opioids such as morphine have been used for thousands of years and are deemed the most effective method for treating pain. However, opioids can have detrimental effects if used illicitly or over an extended period of time. Intriguingly, most of the clinically used opioids act on the mu opioid receptor (µOR). Hence, efforts in recent decades have focused on other opioid receptors to treat pain and other disorders. The delta opioid receptor (δOR) is one of four opioid receptors expressed in the central and peripheral nervous system. The δOR has attracted much attention as a potential target for a multitude of diseases and disorders including substance and alcohol use disorders, ischemia, migraine, and neurodegenerative diseases. However, to date, no δOR agonists, or drugs that act directly at the δOR, have been successful as clinical candidates. Nonetheless, the therapeutic potential of the δOR necessitates the targeting its pharmacologically. In this dissertation, I highlight peptide-based modulation as well as the identification of novel agonists at the δOR. I report research findings in the context of biased agonism at δOR, which is a hypothesized cellular signaling mechanism with potential therapeutic benefits. The focus on this work is the molecular determinants of biased agonism, which were investigated using a combination of cellular and computational approaches.  </p>

Abstract Cellular signaling by G protein-coupled receptors (GPCRs) governs a wide array of physiological functions throughout the body. The human δ-opioid receptor (hδOR) is a GPCR that modulates the sensation of pain and mood and has great potential for the treatment of pain and a variety of neurological disorders. A common single-nucleotide polymorphism (SNP) in the extracellular N-terminal tail of hδOR changes Phe to Cys at position 27. Using various biochemical and cell biological methods, the study demonstrates that several events during receptor biosynthesis and cell surface delivery are affected by the SNP. These events participate in the multifaceted regulation of the receptor and modulate receptor behavior at the cell surface. Two distinct pathways were shown to scrutinize the quality of the synthesized hδOR in the endoplasmic reticulum (ER) and target some for degradation in N-glycan-dependent and -independent ways. The hδORCys27 that matures inefficiently required N-glycan-mediated interactions with the lectin-chaperone calnexin to be expressed in a fully functional form at the cell surface, whereas the N-glycan-independent pathway was sufficient for hδORPhe27. For both variants, the N-glycan-independent quality control, which is likely to operate as a back-up pathway, led to a more rapid export from the ER and receptors at the cell surface that were less stable. Receptor dimerization emerged as an important regulatory step for receptor cell surface delivery. In co-transfected cells, interactions between the newly-synthesized variants led to the retention and subsequent ER-associated degradation of hδORPhe27. This dominant-negative attenuation of hδORPhe27 cell surface expression by hδORCys27 may have unpredictable consequences for opioid signaling in heterozygous individuals. Finally, the study shows that N-acetylgalactosamine (GalNAc)-type O-glycosylation catalyzed in the Golgi modulates hδOR expression at the cell surface by enhancing receptor stability and inhibiting constitutive downregulation. The modification of Ser residues in the receptor N-terminus by GalNAc-transferase 2 was affected by the SNP, which presents another distinction in the cellular processing of the two variants. The findings highlight the importance of the biosynthetic pathway in the regulation of GPCR behavior and pave way for strategies for treatments targeting GPCRs at this level. / Tiivistelmä Solujenvälisellä viestinnällä on keskeinen tehtävä kehon kaikissa toiminnoissa. δ-opioidireseptori (δOR) on solusignalointiin erikoistuneen kalvoproteiiniperheen (G-proteiiniin kytketyt reseptorit) jäsen, joka ohjaa kivuntuntemusta ja mielialoja. Sitä pidetään mahdollisena lääkekehityksen kohteena paitsi kivunlievityksen, myös useiden neurologisten häiriöiden hoidossa. δOR ilmenee kahtena polymorfisena muotona sen solunulkoisessa osassa tapahtuneen aminohappomuutoksen vuoksi (Phe27Cys). Työssä tutkittiin reseptorin glykosylaatiota ja dimerisaatiota, jotka säätelevät sen prosessointia, käyttäytymistä ja toimintaa. Käyttäen useita biokemiallisia ja solubiologisia menetelmiä työssä osoitettiin polymorfian vaikuttavan useisiin prosessointivaiheisiin ja muokkaavan siten reseptorin viestintää. Proteiinien laadunvalvontakoneiston havaittiin säätelevän reseptorin siirtymistä endoplasmakalvostolta solun pinnalle kahdella eri mekanismilla ohjaten osan reseptoreista hajotukseen. Toisin kuin Phe27-variantin, tehottomasti kypsyvän Cys27-variantin laadunvalvonta on riippuvainen reseptoriin liittyvistä N-glykaaneista ja näihin sitoutuvasta kaitsijaproteiinista, kalneksiinista. Reseptorivariantit, joista N-glykaanit puuttuvat, siirtyvät nopeammin solukalvolle, mutta ne ovat epästabiileja ja häviävät nopeasti solun pinnalta. Vaihtoehtoinen N-glykaaneista riippumaton laadunvalvontamekanismi sallii myös inaktiivisen Cys27-variantin pääsyn solun pinnalle. Varianttien dimerisoitumisen osoitettiin säätelevän niiden kuljetusta soluissa. Cys27-variantin havaittiin sitoutuvan Phe27-varianttiin aikaisessa biosynteesivaiheessa ja ohjaavan osan siitä hajotukseen. Tällä voi olla suuri merkitys opioidiviestinnässä molempia alleeleja kantavilla henkilöillä. Työssä havaittiin myös GalNAc-transferaasi-2-entsyymin ohjaavan Golgin laitteessa tapahtuvaa reseptorin O-glykosylaatiota. Se glykosyloi reseptorin solunulkoisen osan seriinitähteitä (Ser6, Ser25, Ser29), stabiloiden siten solun pinnan reseptoreita ja tehostaen niiden viestintää. Lisäksi havaittiin eroja varianttien O-glykosylaatiossa, mikä voi osaltaan selittää varianttien ilmentymisessä todettuja eroja. Tutkimus luo uutta tietoa biosynteesireitin merkityksestä G-proteiiniin kytkettyjen reseptorien säätelyssä sekä antaa pohjaa keinoille, joilla tätä voitaisiin hyödyntää farmakologisesti.

Les dérivés de l’opium (opioïdes) et du cannabis (cannabinoïdes) présentent de nombreuses propriétés intéressantes. Suite à l’identification de leurs récepteurs respectifs, diverses stratégies pharmacologiques ont tenté d’exploiter leurs propriétés analgésiques. Le clonage des récepteurs cannabinoïdes CB1 et CB2 a favorisé la découverte de composés endogènes pour ces récepteurs, les endocannabinoïdes, dont les deux plus étudiés sont l’anandamide et le 2-arachidonyl glycérol (2-AG). Cette découverte a également mené à l’identification d’enzymes qui catalysent l’inactivation de ces cannabinoïdes endogènes : une amidohydrolase des acides gras ou FAAH ainsi qu’une monoacylglycérol lipase ou MAGL. Le système cannabinoïde endogène est régulé à la hausse dans une variété de processus pathologiques, tels que les douleurs inflammatoire et neuropathique. Cette augmentation est habituellement interprétée comme une réaction physiologique visant à rétablir l’homéostasie et elle a notamment été observée en périphérie. Les endocannabinoïdes semblent donc agir de façon spécifique à des moments clés dans certains tissus ciblés afin de minimiser les conséquences reliées au déclenchement de ces douleurs. Cette observation est très intéressante d’un point de vue thérapeutique puisqu’elle suggère la possibilité de cibler les enzymes de dégradation des endocannabinoïdes dans le but d’augmenter leurs concentrations locales et d’ainsi prolonger leur action neuromodulatrice. En périphérie, l’activation des récepteurs cannabinoïdes induit des effets antinociceptifs bénéfiques tout en minimisant les effets indésirables souvent associés à leur activation centrale. Nous avons orienté nos travaux vers la modulation périphérique de ce système endogène à l’aide d’inhibiteurs des enzymes de dégradation des endocannabinoïdes afin d’évaluer leur potentiel thérapeutique et d’élucider les mécanismes d’action qui sous-tendent leurs effets dans des modèles animaux de douleurs inflammatoire et neuropathique. Nous avons démontré que cette approche permet de soulager les symptômes associés à ces deux types de douleurs, et ce via les récepteurs CB1 et CB2. Les systèmes cannabinoïde et opioïde présentent des similitudes, dont des localisations similaires le long des voies de la douleur, des mécanismes d’action relayés par des récepteurs couplés aux protéines G et des propriétés pharmacologiques communes telles que l’analgésie. Le système opioïde est impliqué dans les effets antinociceptifs induits par les cannabinoïdes. À l’inverse, le rôle joué par le système cannabinoïde dans ceux induits par la morphine demeure incertain. Nous avons démontré que les effets antinociceptifs périphériques et spinaux produits par la morphine sont diminués chez les souris génétiquement modifiées chez lesquelles l’expression des récepteurs CB1 ou CB2 a été éliminée, laissant supposer un rôle pour ces récepteurs dans les effets de la morphine. Nous avons de plus démontré que la diminution de l'analgésie produite par la morphine dans ces souris n'est pas causée par un dysfonctionnement des récepteurs opioïdes mu (MOP) ni par une régulation à la baisse de ces récepteurs. Nos résultats confirment l'existence d'interactions fonctionnelles entre les systèmes cannabinoïde et opioïde au niveau périphérique et spinal. Ces observations sont prometteuses d’un point de vue thérapeutique puisqu’une modulation périphérique ciblée des niveaux d’endocannabinoïdes et d’opioïdes endogènes permettrait de produire des effets analgésiques bénéfiques potentiellement synergiques tout en minimisant les effets indésirables associés à l’activation centrale de ces systèmes. / Opium (opioids) and cannabis (cannabinoids) derivatives present many interesting properties. Following the identification of their respective receptors, various pharmacological strategies have tried to exploit their analgesic properties. The cloning of cannabinoid CB1 and CB2 receptors has promoted the discovery of endogenous agonists of these receptors named endocannabinoids. The two mostly studied endocannabinoids are anandamide and 2-arachidonoyl glycerol (2-AG). This has also led to the identification of enzymes that catalyze the inactivation of these endogenous cannabinoids: a fatty acid amide hydrolase or FAAH and a monoacylglycerol lipase or MAGL. It is known that the endogenous cannabinoid system is upregulated in a variety of pathological processes, such as inflammatory and neuropathic pain. This increase is usually interpreted as a physiological response to restore homeostasis and it was particularly observed in the periphery. Endocannabinoids seem to act specifically at key moments in targeted tissues to minimize the consequences related to the onset of pain. This observation is very interesting from a therapeutic perspective because it suggests the possibility of targeting the endocannabinoid degrading enzymes in order to increase their local concentrations and thus prolong their neuromodulatory action. At the peripheral level, the activation of cannabinoid receptors induces beneficial antinociceptive effects while minimizing side effects often associated with their central activation. We focused our work on the peripheral modulation of this endogenous system using inhibitors of endocannabinoid degrading enzymes to assess their therapeutic potential and to elucidate the mechanisms of action underlying their effects in animal models of inflammatory and neuropathic pain. We have demonstrated that this approach can relieve the symptoms associated with these two types of pain, through the activation of CB1 and CB2 receptors. The opioid and cannabinoid systems have similarities, including comparable locations along the pain pathways, mechanisms of action relayed by G protein-coupled receptors and common pharmacological properties such as analgesia. The opioid system is involved in the antinociceptive effects induced by cannabinoids. In contrast, the participation of the cannabinoid system in those induced by morphine remains uncertain. We have demonstrated that peripheral and spinal antinociceptive effects induced by morphine are reduced in genetically modified mice in which the expression of CB1 and CB2 receptors was eliminated, suggesting a role for these receptors in the effects of morphine. We have further demonstrated that the decrease in morphine-induced analgesia in these mice is not caused by a malfunction of the mu opioid receptors (MOP) or by a down-regulation of these receptors. Our results confirm the existence of functional interactions between cannabinoid and opioid systems at the peripheral and spinal levels. These findings are promising from a therapeutic perspective since a targeted modulation of the levels of endocannabinoids and endogenous opioids would induce potentially synergistic beneficial analgesic effects while minimizing side effects associated with the central activation of these systems.